Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant S-1 versus retinoic acid + S-1 versus GEMOX after resection of intrahepatic cholangiocarcinoma
ChiCTR2100050225Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur, tretinoin, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC) (3 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Overall survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
tegafurtretinoingemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2100050225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050225.